Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by themagicboxon Feb 04, 2020 11:22am

92 Views

Post# 30639883

RE:RE:RE:RE:RE:RE:Study requires over 360 patients

Depends on what you mean by pay "well"

Its $50/visit for a total of 6 visits. Verified through the ate clinical trial information package.

To me thats peanuts. To some its worth more.

Retirements wrote: I couldnt help myself and ask the why lol. I see your point and I'm most likely wrong about the dropout still counting. 2 weeks is a short duration but if they pay well for taking it then people might just go with the pain.

Bullboard Posts

A potential breakthrough in spinal cord and optic nerve injury treatment